Personalized Medicine News and Research

RSS

Report on public health in an era of genomic and personalized medicine

The major challenge for public health in the era of genomics is to generate the base of evidence necessary to demonstrate when use of genomic information in public health can improve health outcomes in a safe, effective and cost-effective manner, participants at an international meeting have concluded.

1 Dec 2010

New cerebrospinal fluid biomarkers to monitor Parkinson's disease

KineMed Inc. presents data on the new use of cerebrospinal fluid biomarkers of microtubule-mediated neuronal transport for the monitoring of disease progression and the advancement of therapeutic interventions in Parkinson's disease, a debilitating neurological condition with considerable unmet need for new treatments.

1 Dec 2010

Precision Therapeutics to present abstracts on breast cancer therapy at San Antonio Symposium

Precision Therapeutics will present two abstracts at the 33rd Annual San Antonio Breast Cancer Symposium, which will be held December 8-12, 2010 in San Antonio, Texas.

1 Dec 2010

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

A new finding out in the December 1st issue of Genes & Development offers insight into a new treatment avenue for two painful inflammatory diseases: Crohn's Disease and sarcoidosis.

30 Nov 2010

Quintiles, London Genetics enter strategic alliance to offer pharmacogenetics solutions for personalized medicine

Quintiles, the world's leading biopharmaceutical services company, and London Genetics, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the biopharmaceutical industry innovative pharmacogenetics solutions to advance personalized medicine. Financial terms were not disclosed.

30 Nov 2010

IRIS announces product acquisition from BioMicro Systems

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and a provider of high value personalized medicine products and testing services, announced today that it has acquired the assets of a multi-purpose, bench-top instrument platform for automating highly repetitive, manual laboratory protocols for (F)ISH (fluorescence in-situ hybridization) testing and other slide-based cytogenetic applications.

30 Nov 2010

Personalized oncology requires new paradigm for drug development, experts say

Millions of cancer patients worldwide may soon be able to receive more effective, personalized treatments for their disease thanks to developments in the understanding of cancer biology, experts will say at the Cancer Biology for Clinicians Symposium organized by the European Society for Medical Oncology (ESMO) in Nice this week.

25 Nov 2010

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

For the third year in a row, the American Society of Clinical Oncology (ASCO) has included Erbitux® (cetuximab) research in its annual report, Clinical Cancer Advances, which features the most significant studies of 2010. The report cites as a notable advance this year the finding that BRAF mutation status is a prognostic, not predictive, marker for Erbitux efficacy in metastatic colorectal cancer (mCRC).

23 Nov 2010

Ontario Cancer Plan third edition to address growing needs

The third edition of the Ontario Cancer Plan (OCP) ensures our cancer system serves the changing and growing needs of Ontarians. The Cancer Plan outlines priorities for cancer services, sets a course to transform cancer services from the patient perspective, and is driven by a commitment to quality across the cancer journey - from prevention to survivorship or palliative care - as the most effective way to manage cancer.

23 Nov 2010

New I-SPY 2 study to evaluate effectiveness of medical treatment for breast cancer

A clinical trial that aims to speed up the study of new treatments for certain subtypes of breast cancer now has a designated study site at the Diane O'Connor Thompson Breast Center at the University of Colorado Hospital.

20 Nov 2010

Siemens to unveil Biograph mMR system at RSNA Annual Meeting

At the 96th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), November 28 - December 2 in Chicago, Siemens Healthcare (Booth #822, East Building/Lakeside Center, Hall D) will unveil the Biograph mMR, the world's first integrated whole-body molecular Magnetic Resonance (MR) system with simultaneous data acquisition technology, currently undergoing clinical use testing.

20 Nov 2010

Rheonix receives U.S patent for microfluidic device

Rheonix, Inc., developer of the Rheonix CARD system to provide multiplexed endpoint analysis for a wide breadth of diagnostic applications, announced that on November 16, 2010 the U.S. Patent and Trademark Office issued Patent Number 7,832,429 "Microfluidic Pump and Valve Structures and Fabrication Method" to the Company.

18 Nov 2010

New pharmacogenetic test enables a personalized medicine approach

Luminex Corporation, today announced that it has commercially launched its first pharmacogenetic test, the xTAG CYP2D6 Kit, which recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

From Luminex 17 Nov 2010

Pharmigene receives patent for methods to detect genetic alleles in SJS and TENS

Pharmigene, a leader in advancing personalized medicine and reducing severe adverse reactions to drugs through genetic-based diagnostic solutions, announced it has been granted patents in the United States, Europe, Australia, Singapore and Taiwan. The patents cover methods to detect the presence of key genetic alleles in individual patients being considered for treatment with drugs that have been linked to the development of adverse drug reactions including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

17 Nov 2010

33rd CTRC-AACR Symposium to feature breast cancer research

The 33rd CTRC-AACR San Antonio Breast Cancer Symposium will feature the latest findings in prevention, epidemiological, laboratory, translational and clinical breast cancer research. This year's symposium will highlight new therapies in the pipeline, new approaches with existing agents and emerging biology that will affect the quest for personalized medicine.

12 Nov 2010

Plexxikon's PLX4032 shows positive data in patients with metastatic melanoma

Plexxikon today announced positive preliminary data from a pivotal Phase 2 clinical trial of PLX4032 (RG7204) in metastatic melanoma, showing significant tumor shrinkage in the majority of patients.

8 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

ArcticDx develops test to determine inherited risk for AMD

Established in 2007 and based in Toronto, ArcticDx has developed a test, Macula Risk-, the first of its kind and specifically designed to determine one's inherited risk for age-related macular degeneration (AMD), the most common form of acquired blindness in the developed world, affecting over 10% of individuals. ArcticDx will use the PBDF investment to undertake studies in support of a planned filing for Food and Drug Administration (FDA) approval for Macula Risk.

2 Nov 2010

New targeted therapy shows positive results in patients with lung cancer

A UC Irvine oncologist's work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer. The results were published Thursday in the New England Journal of Medicine.

2 Nov 2010

New REACT medical trial for early diagnosis of lung cancer

Physicians at El Camino Hospital are starting a medical trial called REACT that they hope may give doctors a new and cost-effective tool for early diagnosis of lung cancer, the deadliest of the common cancers.

2 Nov 2010

Personalized Medicine News and Research

Report on public health in an era of genomic and personalized medicine

New cerebrospinal fluid biomarkers to monitor Parkinson's disease

Precision Therapeutics to present abstracts on breast cancer therapy at San Antonio Symposium

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

Quintiles, London Genetics enter strategic alliance to offer pharmacogenetics solutions for personalized medicine

IRIS announces product acquisition from BioMicro Systems

Personalized oncology requires new paradigm for drug development, experts say

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

Ontario Cancer Plan third edition to address growing needs

New I-SPY 2 study to evaluate effectiveness of medical treatment for breast cancer

Siemens to unveil Biograph mMR system at RSNA Annual Meeting

Rheonix receives U.S patent for microfluidic device

New pharmacogenetic test enables a personalized medicine approach

Pharmigene receives patent for methods to detect genetic alleles in SJS and TENS

33rd CTRC-AACR Symposium to feature breast cancer research

Plexxikon's PLX4032 shows positive data in patients with metastatic melanoma

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

ArcticDx develops test to determine inherited risk for AMD

New targeted therapy shows positive results in patients with lung cancer

New REACT medical trial for early diagnosis of lung cancer

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News